Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) Gross Margin (2016 - 2025)

Dexcom (DXCM) has disclosed Gross Margin for 16 consecutive years, with 62.93% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin rose 404.0% to 62.93% in Q4 2025 year-over-year; TTM through Dec 2025 was 60.1%, a 36.0% decrease, with the full-year FY2025 number at 60.1%, down 36.0% from a year prior.
  • Gross Margin was 62.93% for Q4 2025 at Dexcom, up from 60.48% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 70.09% in Q2 2021 to a low of 56.85% in Q1 2025.
  • A 5-year average of 63.37% and a median of 63.12% in 2022 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: surged 721bps in 2021, then plummeted -552bps in 2022.
  • Dexcom's Gross Margin stood at 67.69% in 2021, then decreased by -2bps to 66.4% in 2022, then fell by -4bps to 63.47% in 2023, then decreased by -7bps to 58.9% in 2024, then grew by 7bps to 62.93% in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Gross Margin are 62.93% (Q4 2025), 60.48% (Q3 2025), and 59.53% (Q2 2025).